Minimal Propofol Dosing Triggers Propofol-Related Infusion Syndrome (PRIS) in a Geriatric Burn Patient: A Brief Report of Complex Burn Pharmacokinetics

<b>Background</b> Propofol is an intravenous hypnotic agent widely used for anesthesia and sedation in critically ill, mechanically ventilated patients due to its rapid onset and offset, which facilitate ventilator weaning and extubation. Despite these benefits, propofol's lipid emulsion formulation poses an infection risk and is associated with propofol-related infusion syndrome (PRIS). PRIS is characterized by acute bradycardia that is resistant to treatment and may progress to asystole. <b>Objectives</b> We report the case of a 76-year-old woman who sustained full-thickness burns covering 30% of her total body surface area, involving the chest, abdomen, bilateral upper extremities, and right leg. She was sedated with propofol during her critical care management. The patient's clinical course was closely monitored for complications, and risk factors associated with PRIS were assessed. <b>Results</b> The patient developed PRIS despite the absence of typical risk factors, including high-dose propofol exposure, steroid therapy, young age, or inborn errors of metabolism. Despite supportive care and efforts to mitigate PRIS progression, her clinical condition deteriorated, resulting in a fatal outcome. <b>Discussion</b> This case highlights a rare occurrence of PRIS in a patient without common risk factors, emphasizing the need for continued vigilance in monitoring, even in atypical cases. Further investigation into alternative risk factors and methods for early detection is warranted. <b>Conclusion</b> The senior care pharmacist plays an important role in the prevention, early detection, and management of PRIS. This case emphasizes the importance of daily clinical pharmacist reviews and highlights the critical role of senior care pharmacists in early identification and management of PRIS, even among low risk older adult patients receiving low-dose propofol regimens.